Significant advancements in the developmental pipeline across various oncological disorders, infectious diseases and genetic disorders have amplified the interest of various pharmaceutical establishments and have inspired research groups across the world, to focus their efforts on the development of RNAi therapeutics. Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.

To order this 350+ page report, which features 130+ figures and 190+ tables, please visit this https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html

The USD 9.2 billion (by 2030) financial opportunity within the RNAi therapeutics market has been analyzed across the following segments:
 Key therapeutic areas
 Oncological disorders
 Infectious diseases
 Genetic disorders
 Ophthalmic disorders
 Hepatic disorders
 Respiratory disorders

 Type of RNAi molecule
 siRNA
 miRNA
 shRNA
 sshRNA
 DNA

 Route of administration
 Subcutaneous
 Intravenous
 Intradermal
 Intratumoral
 Intravitreal
 Oral
 Intramuscular

 Key geographical regions
 North America
 Europe
 Asia Pacific and the Rest of the World

 Leading Players

The RNAi Therapeutics Market (2nd Edition), 2019-2030 report features the following companies, which we identified to be key players in this domain:
 Quark Pharmaceuticals
 Alnylam Pharmaceuticals
 Dicerna Pharmaceuticals
 Souzhou Ribo Life Sciences
 Olix Pharmaceuticals
 Sirnaomics
 Ariz Precision Medicine
 Arrowhead Pharmaceuticals
 Gradalis
 Benitec Biopharma

Table of Contents

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. COMPETITIVE LANDSCAPE

5. COMPANY COMPETITIVENESS ANALYSIS

6. LATE STAGE RNAi THERAPEUTICS

7. TECHNOLOGY PLATFORMS AND DELIVERY SYSTEMS

8. KEY THERAPEUTIC INDICATIONS

9. CLINICAL TRIAL ANALYSIS

10. PATENT ANALYSIS

11. RECENT PARTNERSHIPS

12. FUNDING AND INVESTMENT ANALYSIS

13. PROMOTIONAL ANALYSIS

14. MARKET SIZING AND OPPORTUNITY ANALYSIS

15. RNAi IN DIAGNOSTICS

16. SERVICE PROVIDERS FOR RNAi THERAPEUTICS

17. SWOT ANALYSIS

18. CONCLUSION

19. INTERVIEW TRANSCRIPT(S)

20. APPENDIX 1: TABULATED DATA

21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]